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A B S T R A C T
Background
After surgery for localised breast cancer, adjuvant radiotherapy improves both local control and breast cancer specific survival. In
patients at risk of harbouring micro-metastatic disease, adjuvant chemotherapy improves 15-year survival. However, the best sequence
of administering these two types of adjuvant therapy for early stage breast cancer is not clear.
Objectives
To determine the effects of different sequencing of chemotherapy and radiotherapy for women with early breast cancer.
Search methods
We searched the Cochrane Breast Cancer Group Specialized Register (10 March 2005). Details of the search strategy and methods of
coding are described in the Group’s module inThe Cochrane Library. We extracted studies that had been coded as ’early’, ’chemotherapy’
and ’radiotherapy’.
Selection criteria
Randomised controlled trials evaluating different sequencing of chemotherapy and radiotherapy were included.
Data collection and analysis
We assessed the eligibility and quality of the identified studies and extracted data from the published reports of the included studies.
We derived odds ratios (OR) and risk ratios from the available numerical data. Hazard ratios were extracted directly from text. Toxicity
data were extracted, where reported. We used a fixed-effect model for meta-analysis and conducted analyses on the basis of the method
of sequencing of the two treatments.
Main results
Three trials reporting two different sequencing comparisons were identified. There were no significant differences between the various
methods of sequencing adjuvant therapy for survival, distant metastases or local recurrence, based on 853 randomised patients in two
trials. One of these two trials (647 women) provided data on toxicity. Haematological toxicity (OR 1.43, confidence interval (CI) 1.01
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to 2.03) and oesophageal toxicity (OR 1.44, CI 1.03 to 2.02) were significantly increased with concurrent therapy, and nausea and
vomiting were significantly decreased (OR 0.70, CI 0.50 to 0.98). Other measures of toxicity did not differ between the two types of
sequencing. On the basis of one trial (244 women), radiotherapy before chemotherapy was associated with a significantly increased
risk of neutropenic sepsis (OR 2.96, 95%CI 1.26 to 6.98) compared with chemotherapy before radiotherapy, but other measures of
toxicity were not significantly different.
Authors’ conclusions
The data included in this review, from three well conducted randomised trials, suggest that different methods of sequencing chemo-
therapy and radiotherapy do not appear to have a major effect on survival or recurrence for women with breast cancer if radiation
therapy is commenced within 7 months after surgery.
P L A I N L A N G U A G E S U M M A R Y
Sequencing of chemotherapy and radiotherapy for women following surgery for early breast cancer
Both chemotherapy and radiotherapy reduce the risk of breast cancer recurring and the risk of dying from breast cancer. Generally
these therapies are given after surgery but there is uncertainty about whether they should be given at the same time (concurrently) or
one after the other (sequentially). If they are used sequentially, the radiotherapy or the chemotherapy could be used first and concerns
have been expressed that the effectiveness of the therapy that is delayed might be reduced. However, it has also been suggested that
using chemotherapy and radiotherapy at the same time will be less beneficial than keeping them separate. This review examined current
evidence on the best way to administer chemotherapy and radiotherapy following breast conserving surgery. We were able to include
three randomised trials. Two of these, with a total of 853 women, assessed radiotherapy and chemotherapy given at the same time versus
chemotherapy given first followed by radiotherapy. The third trial randomised 244 women to radiotherapy followed by chemotherapy
versus chemotherapy followed by radiotherapy. The evidence produced by these three well conducted trials suggests that recurrence of
a woman’s cancer and her chances of dying from breast cancer are similar regardless of the order of the treatments, provided that both
radiotherapy and chemotherapy are commenced within seven months of the surgery. The trials provided limited information regarding
adverse events, side effects, or quality of life associated with the different sequences of treatment, but the limited evidence available
does suggest that the frequency and severity of side effects of chemotherapy and radiotherapy are similar regardless of which sequence
is used. It should be noted, however, that the women in these trials were treated, on average, ten years ago. As a result the trials do not
assess the modern types of radiotherapy, and newer types of chemotherapy (such as taxanes) or other drugs (such as Herceptin). We
will add relevant trials which include these newer treatments to future updates of this review.
B A C K G R O U N D
For women with localised breast cancer who undergo conservative
surgery or mastectomy, adjuvant radiotherapy reduces consider-
ably the risk of local recurrence and improves breast cancer specific
survival (EBCTCG 2005a; Ragaz 2005). Adjuvant chemotherapy
has also been shown to improve 15-year survival by about 10%
for women aged under 50 years and by about 3% for women aged
50 to 69 years (EBCTCG 2005b).
Current practices for the sequencing of radiotherapy and chemo-
therapy include administering chemotherapy before radiotherapy,
administering chemotherapy and radiotherapy concurrently, or
’sandwiching’ radiotherapy in the middle of the chemotherapy
course. It is not clear which of these different sequences is themost
effective for women with early stage breast cancer. It has been sug-
gested that the sequence of these two treatments may affect patient
outcome (Recht 1996). For example, a delay in initiating radio-
therapy was found to increase the risk of local recurrence (odds ra-
tio (OR) 2.28, 95% confidence interval (CI) 1.45 to 3.57) (Huang
2003). However, a delay in commencing chemotherapy may also
have a detrimental effect on survival. A published randomised trial
initially found a non-significant improvement in overall survival
if chemotherapy was given first (Recht 1996) but longer follow up
did not reveal any difference in the rates of local or distant recur-
rence or death between the two treatment groups (Bellon 2001).
Additionally, some non-randomised studies have suggested that
delaying radiotherapy while chemotherapy is administered first
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could increase local recurrence rates (Buchholz 1993; Buchholz
1999; Buzdar 1993; Donato 2004; Hartsell 1995; Leonard 1995;
McCormick 1996;Meek1996; Recht 1991; Slotman 1994). Con-
versely, a delay in the administration of systemic chemotherapy
while radiotherapy is delivered could allow the proliferation of
micro-metastatic disease to an extent that it can no longer be dealt
with adequately by the chemotherapy.
In many parts of the world there are waiting lists for radiother-
apy (Ash 2000; Kenny 2004; MacKillop 1994; MacKillop 1995).
Therefore, the delivery of chemotherapy first allows patients to
continue with their treatment while they wait for radiotherapy to
start and this may make management of the waiting lists for ra-
diotherapy easier (Kenny 2004).
If a systematic review helps to resolve this uncertainty about the
relative effects of different sequences of chemotherapy and radio-
therapy, it will assist in making these choices. For example, if it
shows that sequencing of the two treatments makes little or no
difference for cancer related outcomes such as survival and lo-
cal recurrence, then choosing to give chemotherapy first may be
preferable for both logistic reasons and patient preference.
O B J E C T I V E S
To determine the effects of different sequencing of radiotherapy
and chemotherapy for women with early stage breast cancer who
have been treated surgically.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials evaluating different ways of sequencing radio-
therapy and chemotherapywere eligible. The comparison between
different sequences had to be un-confounded (i.e. the randomised
groups differed only in relation to the sequencing of the two treat-
ments). Trials incorporating the use of other adjuvant treatments,
such as monoclonal antibodies or hormonal therapy, were eligible
if these other treatments were applied in both groups in the ran-
domised trial. Published and unpublished studies were eligible.
Types of participants
Women with surgically treated, histologically confirmed early
stage breast cancer who required both adjuvant chemotherapy and
radiotherapy were included. Early breast cancer included tumours
classified as UICC stage T1-3N0-1M0. Surgery could comprise
mastectomy, lumpectomy, wide local excision or quadrantectomy,
with or without axillary dissection, axillary sampling or sentinal
node biopsy. Women who had previously received adjuvant ther-
apy for breast cancer were not eligible.
Types of interventions
The following comparisons were eligible:
1) Adjuvant radiotherapy followed by adjuvant chemotherapy ver-
sus adjuvant chemotherapy followed by adjuvant radiotherapy;
2) Adjuvant chemotherapy followed by adjuvant radiotherapy ver-
sus a ’sandwich technique’ (when one or more courses of chemo-
therapy are followed by radiotherapy, which is followed by further
chemotherapy);
3) Adjuvant chemotherapy followed by adjuvant radiotherapy ver-
sus concurrent adjuvant chemotherapy and radiotherapy.
Chemotherapy regimens included those delivered at standard
doses (i.e. not high dose), and could include drugs such as cy-
clophosphamide, 5-fluorouracil, anthracyclines, taxanes and other
agents.
Radiotherapy had to be delivered to the breast or chest wall, in-
cluding or not including the supraclavicular fossa and axilla. Stan-
dard fractionation (1.8 to 3.0 Gy per fraction) had to be used,
delivering a total of 40 to 61 Gy at the reference point. It could
include a boost (using electrons, interstitial therapy or external
beam) or new techniques.
Types of outcome measures
Primary outcomes: local recurrence in the ipsilateral (i.e. same)
breast and cause-specific mortality.
Secondary outcomes: overall survival; distant metastases (in isola-
tion or at the same time as local recurrence); relapse-free survival;
subsequent mastectomy; harms, including acute and late effects of
radiotherapy, chemotherapy-related toxicity; ability to deliver the
prescribed dose of chemotherapy; ability to deliver the prescribed
dose of radiotherapy; costs; quality of life, and consumer prefer-
ence.
We set an arbitrary threshold of 80% when assessing the ability to
deliver the prescribed dose of chemotherapy or radiotherapy.
We defined local recurrence as including recurrence in the ipsilat-
eral breast (i.e. the breast in which cancer had been diagnosed),
the skin and parenchyma.
Search methods for identification of studies
We searched the Cochrane Breast Cancer Group Specialized Reg-
ister on 10 March 2005. Details of the search strategy used by the
Group to create this register and the procedure used to code the
references are described in the Group’s module in The Cochrane
Library. We extracted studies coded with each of the three terms
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’early’, ’chemotherapy’ and ’radiotherapy’ for consideration. This
identified a total of 85 articles.
We also conducted electronic searches of additional databases.
These included CENTRAL (Issue 4 2005), MEDLINE (1996 to
2005), CINAHL, Current Contents (1998 to June 2005) and Sci-
ence Citation Index.
Our search strategy for searching MEDLINE in December 2005
is given below. We adapted this for the other databases.
1. RANDOMIZED CONTROLLED TRIAL.pt
2. CONTROLLED CLINICAL TRIAL.pt
3. RANDOMIZED CONTROLLED TRIALS.sh
4. RANDOM ALLOCATION.sh
5. DOUBLE BLIND METHOD.sh
6. SINGLE BLIND METHOD.sh
7. 1 or 2 or 3 or 4 or 5 or 6
8. (ANIMALS not HUMAN).sh
9. 7 not 8
10. CLINICAL TRIAL.pt
11. exp CLINICAL TRIALS/
12. (clin$ adj25 trial$).ti,ab
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or
mask$)).ti,ab
14. PLACEBOS.sh
15. placebo$.ti,ab
16. random$.ti,ab
17. RESEARCH DESIGN.sh
18. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 18 not 8
20. 19 not 9
21. 9 or 20
22. Breast Neoplasms.me
23. breast cancer.ti,ab,sh,kw
24. breast tumour.ti,ab,sh,kw
25. Mamm$ near Carcinoma.kw,sh,sb
26. Carcinoma, Ductal, Breast.mp
27. 22 or 23 or 24 or 25 or 26
28. Chemotherapy, adjuvant.me
29. adjuvant chemotherapy.kw,sh,ti,ab
30. Antineoplastic Combined Chemotherapy Protocols
31. Breast Neoplasms/dt
32. cyclophosphamide/tu
33. Doxorubicin/tu
34. Methotrexate/tu
35. fluorouracil/tu
36. Carcinoma, Ductal, Breast/dt
37. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. radiotherapy, adjuvant.me
39. radiotherapy.sh,kw,ti,ab
40. radiation therapy.sh,kw,ti,ab
41. Breast Neoplasms/rt
42. Carcinoma, Ductal, Breast/rt
43. 38 or 39 or 40 or 41 or 42
44. exp MASTECTOMY, SUBCUTANEOUS/
45. exp MASTECTOMY, MODIFIED RADICAL/
46. mastectomy.mp
47. exp MASTECTOMY, EXTENDED RADICAL/
48. exp MASTECTOMY, SEGMENTAL/
49. MASTECTOMY, RADICAL/
50. exp MASTECTOMY/
51. exp MASTECTOMY, SIMPLE
52. Breast neoplasms/su
53. mastectomy.kw,ab,ti,sh.
54. lumpectomy.kw,ab,ti,sh
55. wide local excision.kw,ab,ti,sh
56. quadrantectomy.kw,ab,ti,sh.
57. Neoplasm Recurrence, Local/su
58. 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or
54 or 55 or 56
59. 21 and 27 and 37 and 43 and 58
We searched registers of ongoing clinical trials. These included
the US clinical trials registry (www.clinicaltrials.gov), the Inter-
national Standard Randomised Controlled Trial Number Regis-
ter (www.controlled-trials.com/isrctn), and the UKCCRNational
Register of Cancer Trials. We also searched other sources of un-
published trials (SIGLE, National Research Register) and we con-
tacted researchers to ask if they were aware of any other trials on
this topic.
We handsearched a number of conference proceedings and pub-
lished abstracts:
2001 Adjuvant Therapy for Primary Breast Cancer International
Conference
Era of Hope, Department of Defence Breast Cancer Research Pro-
gram Meeting
2001 and 2003: Primary Therapy of Early Breast Cancer
6th and 7th Nottingham International Breast Cancer Meeting
Conference Report
23rd and 24th Congress of the International Association for Breast
Cancer Research
3rd and 4th Perspectives in Breast Cancer Conference Report
26th and 27th Annual San Antonio Breast Cancer Symposium
4th European Breast Cancer Conference
94th and 95th American Association of Cancer Research
American Society for Clinical Oncology (1995 to 2005)
European Society for Therapeutic and Radiation Oncology (2000
to 2004)
5th and 6th Milan Breast Cancer Conference
Australian Breast Cancer Conference (2004)
27th and 28th Annual Symposium of the American Society of
Breast Disease
CDC Cancer Conference (2003)
British Cancer Meeting Report
Canadian Breast Cancer Research Conference: Reasons for hope
We also checked the citations in eligible articles.
No language restrictions were employed.
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Data collection and analysis
Study selection
All three authors (BH,MLandDF) checked the titles and abstracts
retrieved by all searches. Each author assessed independently the
full text of the studies we thought might be relevant to the review,
resolving differences through discussion. We assessed trials with
the results masked. In cases where only limited data, information
on study methods or both was reported, we requested further
information from the authors of the original articles.
Data extraction
Two authors (BH and ML) performed data extraction, with dis-
agreements resolved by discussion. We contacted the original au-
thors for data from unpublished trials or published trials that did
not report data needed for this review. Data were entered into
RevMan 4.2.8 for analyses. Where possible, we extracted data on
tumour stage, nodal status, margin status, receptor status, hor-
monal manipulation, treatment allocation and surgery performed.
The information we extracted on radiotherapy and chemotherapy
included time from randomisation to the start of radiotherapy and
chemotherapy, duration of chemotherapy, duration of radiother-
apy, radiation dose and dose per fraction. We extracted outcome
data for local recurrence, distant metastases, deaths (cause-specific
and all causes), treatment-related toxicity (including that related
to acute and late effects of radiotherapy and chemotherapy), costs
of treatment, consumer preference and quality of life.
Presentation of data
Dichotomous results are presented as odds ratios with 95% con-
fidence intervals (CI) (Deeks 2003). We used Mantel-Haenszel
methods to calculate pooled results (Greenland 1985; Mantel
1959), and assessed heterogeneity both visually and statistically
using the chi squared test of heterogeneity (Altman 1992, Walker
1988). We did not identify significant heterogeneity among the
results of the trials in the current analysis, but if heterogeneity is
identified in updates of this review, the reasons for it will be ex-
plored and we will make a cautious attempt to explain it.
Analysis
We used the intention-to-treat principle in analysing data from
the trials, and determined a weighted average treatment effect by
using the fixed-effect model to combine results (Mantel 1959) and
RevMan 4.2.8.
The current version of this review does not include any subgroup
analyses because of the lack of data. However, if sufficient data
become available in future updates, we may perform subgroup
analyses to investigate whether the effects of different sequences
of radiotherapy and chemotherapy differ depending upon nodal
status, margin status, receptor status, hormonal manipulation and
tumour stage.
No continuous variables of relevance were reported by the selected
trials. If continuous variables (such as quality of life) are reported
and are to be used in future updates of this review, we will use
recommended methods to collect and combine the data. If such
data had been available for the current version of this review, we
would have used the mean difference method, unless different
scales had been reported in the trials, in which case we would have
used a standardized mean difference to summarize data (Deeks
2003).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
After screening the titles and abstracts retrieved electronically and
by handsearching, we identified 126 reports for possible inclusion
in this review. Further screening of these reduced the number to 37
reports and, where possible, we obtained the full articles for these.
The results presented in these articles weremasked and the remain-
ing text was assessed by two authors (BH and ML). This revealed
that 20 of the reports did not relate to randomised trials (Bellon
2002; Bellon 2004; Buzdar 1993; Cakir 2003; Denham 1995;
Dubey 1999; Faul 1998; Faul 2003; Fiets 2003; Garcia 1996;
Hartsell 1995; Hasbini 2000; Isaac 2002; Lamb 1999; Leonard
1995; Recht 1991; Rubens 1980; Sauer 1996; Stemmer 2003;
Zambetti 1999) and the treatments investigated in six were not eli-
gible for this review (Assersohn 1999; Bellantone 1998; Blomqvist
1992; Donato 2004; Wallgren 1996; Warner 1998). One study
investigated different sequences of therapy, but was confounded
(and, therefore, ineligible) because the chemotherapy regimens
were different in the two randomized groups (Rouesse 2002).Nine
reports did relate to randomised trials that appeared tomeet our in-
clusion criteria (Arcangeli 2006; Bellon 2005; Bellon 2001; Calais
1998a; Calais 1998b; Calais 2002; Calais 2004; Hardenbergh
1999; Recht 1996). One ongoing study was identified (Fernando
1999).
The nine reports that met the inclusion criteria related to three
separate studies because some of the trials had published their
results at different times, with different periods of follow up. In
these cases we used the most recent publication as the main source
for this review, supplementing this with information from earlier
reports if necessary. Thus, for the Bellon 2005 trial, the main
source was the Bellon 2005 article, with three other publications
found for this trial (Bellon 2001;Hardenbergh 1999;Recht 1996).
Similarly, for the Calais 2004 trial, our primary source for data
extraction was Calais 2004, with some information also available
in three other publications (Calais 1998a; Calais 1998b; Calais
2002).
One report (Calais 2004) required translation from French to En-
glish, while another (Garcia 1996) required translation fromSpan-
ish to English.
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Of the three authors we contacted, two provided us with addi-
tional data on their studies (Arcangeli 2006; Rouesse 2002). We
are awaiting further information from one (Bellon 2005).
The three randomised trials included in the current version of this
review randomised a total of 1097 patients. Two studies (Arcangeli
2006; Calais 2004), with a total of 853 patients, compared con-
current chemotherapy and radiotherapy with sequential adminis-
tration of chemotherapy before radiotherapy. The third trial (Bel-
lon 2005) compared radiotherapy followed by chemotherapy to
chemotherapy followed by radiotherapy in 244 patients. Fuller
information on the three trials is given in the ’Characteristics of
included studies’ table.
Risk of bias in included studies
Two reviewers (BH andML) categorised themethodological qual-
ity of each eligible trial using the following system:
A. Low risk of bias. Plausible bias unlikely to seriously alter results.
All of the quality criteria met.
B. Moderate risk of bias. Plausible bias that raises some doubt
about the results. One or more of the quality criteria met.
C. High risk of bias. Plausible bias that seriously weakens confi-
dence in the results. One or more of the quality criteria not met.
Studies were assessed according to the adequacy of concealment
of randomisation and whether the analysis was by intention to
treat. Given the treatments studied in these trials, blinding of
participants and assessors was not possible; therefore we did not
regard blinding as an important feature in our quality assessment.
We did use adequacy of follow up as a quality criterion, setting
an arbitrary threshold of 80% follow up as adequate. We assessed
each trial to determine if the procedures and methods used were
adequate, inadequate or unclear.
Bellon 2005 and Arcangeli 2006 had adequate follow up. Analysis
by intention to treat methods was stated in Arcangeli 2006. We
are seeking further information from Bellon 2005 to determine
if the data were analysed by intention to treat. The adequacy of
concealment of randomisationwas unclear from the reports of each
of the three trials. In Calais 2004, all three criteria were unclear,
perhaps reflecting poor reporting more than a poorly conducted
trial. We will continue to seek additional information from the
author for inclusion in an updated version of this review. The
results of our categorisation are in the ’Characteristics of included
studies’ table.
Effects of interventions
Concurrent treatment versus chemotherapy followed by radio-
therapy
There were two trials, enrolling a total of 853 women, in this
comparison (Arcangeli 2006;Calais 2004). In the results presented
here, ratios of treatment effects are given such that ORs of less
than 1.0 would indicate a beneficial effect of concurrent treatment
compared with sequential treatment (although, as noted below,
most of these results are not statistically significant).
Local recurrence (ipsilateral): both studies reported results for lo-
cal recurrence. There was a total of 14 such recurrences in 853
randomised women. The OR for concurrent therapy compared
with sequential therapy (chemotherapy followed by radiotherapy)
is 1.30 (CI 0.45 to 3.77, P=0.63). There was no heterogeneity (P
= 0.71) between the two trials (Comparisons and data 01.01).
Cause-specific survival: neither trial reported this outcome.
Overall survival: Arcangeli 2006 reported the overall survival in
concurrent and sequential groups at 5 years as being 94.7% and
93.9% respectively, with a non-significant hazard ratio (HR).
Distant metastases: 68 of the women in the two trials combined
had distant metastases diagnosed. The OR is 1.43 (CI 0.86 to
2.37, P=0.16). There was no heterogeneity (P = 0.58) between the
two trials (Comparisons and data 01.02).
Relapse-free survival: no data.
Mastectomy rate: no data.
Harms and toxicity: the Arcangeli 2006 report includes the com-
ment that acute toxicity was “mild in both groups, with infrequent
moist desquamation in limited areas” and the authors indicated
that late toxicity is currently being evaluated and will be reported
separately (Arcangeli 2006). The other trial (Calais 2004), with
647 women, reported harms and toxicity in detail (Comparisons
and data 01.03). No significant difference was found between the
treatment groups for fever, cardiac complications, neutrophil tox-
icity or platelet toxicity. However, oesophageal toxicity (OR 1.44,
CI 1.03 to 2.02, P = 0.03), haematological toxicity (OR 1.43, CI
1.01 to 2.03, P = 0.04) and skin toxicity (OR 1.46, CI 1.00-2.14),
P=0.05) were significantly lower with sequential therapy. Nausea
and vomiting was significantly less common with concurrent ther-
apy (OR 0.70, CI 0.50 to 0.98, P = 0.04).
Ability to deliver the prescribed chemotherapy dose (compliance):
our arbitrary threshold of the delivery of at least 80% of the pre-
scribed chemotherapy was achieved for all women in both trials.
Ability to deliver the prescribed radiotherapy dose (compliance):
all patients in both randomised groups in the Arcangeli 2006 trial
received 100% of their planned radiotherapy, and there was no
significant difference in the total dose delivered in both groups of
Calais 2004.
Costs: no data.
Quality of life: no data.
Consumer preference: no data.
Radiotherapy followed by chemotherapy versus chemotherapy fol-
lowed by radiotherapy
One trial, enrolling 244 women, was available for this comparison
(Bellon 2005). The following results are presented such that an
OR or HR of less than 1.0 favours the group allocated to receive
radiotherapy first.
Local recurrence (ipsilateral): local control was reported but only
as first event data.We are awaiting a reply from the author and will
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modify future updates of this review when these data have been
obtained.
Cause-specific survival: reported.
Overall survival: the HR reported was 0.85 (CI 0.51 to 1.40, P=
0.52) (Bellon 2005) (Additional Table 1).
Distant Metastases: the HR was 0.82 (CI 0.49 to 1.36, P=0.44)
(Additional Table 1).
Relapse-free survival: this outcome was not reported.
Mastectomy rate: this outcome was not reported.
Harms and toxicity: outcomes for toxicity are shown in Compar-
isons and data 02.01 (Bellon 2005). Radiotherapy before chemo-
therapy was associated with significantly more neutropenic sepsis
(OR 2.96, CI 1.26 to 6.98,P=0.02). Non-significant differences
were reported for skin toxicity, subcutaneous toxicity, pneumoni-
tis, lymphoedema and brachial plexopathy. Owing to the small
number of events, many of the effects had wide CIs (Comparisons
and data 02.01).
Ability to deliver the prescribed chemotherapy dose (compliance):
no data.
Ability to deliver the prescribed radiotherapy dose (compliance):
no data.
Costs: no data
Quality of life: no data
Consumer preference: no data
D I S C U S S I O N
For women who elect to have breast conservation surgery for early
breast cancer, achieving and maintaining local control and im-
proving survival are of paramount importance. The Early Breast
Cancer Trialists’ CollaborativeGroup overviewhas shown the ben-
efits of chemotherapy and radiotherapy as adjuvant treatments
(EBCTCG 2005a; EBCTCG 2005b), and this review set out to
explore whether there is an optimal sequencing of adjuvant che-
motherapy and radiotherapy as part of the conservative manage-
ment of women with early breast cancer. We have been able to
include data from three randomised trials of two different com-
parisons of sequencing. The comparisons are concurrent versus se-
quential treatment (with chemotherapy before radiotherapy), and
radiotherapy followed by chemotherapy versus chemotherapy fol-
lowed by radiotherapy. In both comparisons the evidence suggests
that there are no major differences between the sequencing tech-
niques in regard tomortality and local or distant recurrence. There
is some evidence for differences in toxicity between sequencing
techniques but most of the harms reported in the trials were not
significantly different between the randomised groups. No data
were available for costs, quality of life or consumer preference.
Caution in interpreting these results is advised however as given
the low event rate for some endpoints such as local recurrence, the
statistical power for detecting a clinically important risk difference
in such outcomes is very small.
The findings of this review provide reassurance that the general
practice of giving chemotherapy before radiotherapy is not detri-
mental in terms survival and toxicity in comparison with either the
opposite sequence or the concurrent administration of chemother-
apy and radiotherapy. However, some caveats are important in ap-
plying these results to current practice. First, the treatments in the
included trials were given a decade ago on average and the chemo-
therapy regimens may not be considered optimal today. Secondly,
surgical outcomes in the trials might be considered unacceptable
today. Positive surgical margins are an independent predictor of
local recurrence (Leong 2004), but women who had positive sur-
gical margins were eligible for the study of radiotherapy followed
by chemotherapy versus chemotherapy followed by radiotherapy
(Bellon 2005). The standard of practice today would be to try to
ensure negative surgical margins were achieved before radiother-
apy. Finally, although the length of follow up in the included trials
is adequate to detect differences in local recurrences, it is not yet
long enough to assess the effects on breast cancer mortality. Local
recurrence after breast conserving therapy reaches a peak at about
two years (Churn 2001) and continues at one percent per year for
at least the next two decades (Kurtz 1987; Lippman 1995).Distant
recurrences and deaths from breast cancer take longer (EBCTCG
2005a) and would not have been captured with the relatively short
follow up of these trials.
It has not been possible to answer some questions with this initial
version of the review:
(1) Harms, costs, patient preferences and impact on quality of life
The treatment-related toxicity differed little between the sequenc-
ing techniques. There was no information regarding quality of
life, women’s preferences or costs in the included trials. It has been
shown that concurrent chemotherapy and radiotherapy can de-
crease awoman’s quality of life, but this seems similar to that found
with sequential therapy, and theremay be an advantage for concur-
rent therapy arising from its shorter duration (Macquart-Moulin
1999).
(2) The impact of newer chemotherapy regimens and biological
agents
The original standard chemotherapy regimen of CMF (cyclophos-
phamide, methotrexate and 5-fluorouracil) has been superseded
by anthracycline-based regimens, particularly in high-risk younger
women (EBCTCG 2005b). In theory, these regimens should be
less toxic than the older regimens if delivered over the same or
shorter time period. Taxanes (paclitaxel and docetaxel) are new
chemotherapy agents that appear to reduce significantly the risk
of death when used in the adjuvant setting for women with early
breast cancer (Henderson 2003; Martin 2005). There is currently
no information regarding the optimum sequencing of radiother-
apy with taxanes. If taxanes were used sequentially with standard
chemotherapy agents (Henderson 2003), this would lead to an
extended delay in starting radiotherapy, which has the potential to
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increase the local recurrence rate. Reassuringly, in one trial inwhich
radiotherapy was delayed by the delivery of paclitaxel, there was
a reduction in local recurrence for those women who had under-
gone breast conserving therapy and received paclitaxel (Henderson
2003). Furthermore, new agents are continually being developed
for treating women with breast cancer (e.g. trastuzumab (Her-
ceptin®)), but there is little evidence to guide decisions about how
these should be sequenced with radiotherapy.
(3) The impact of new modes of radiotherapy
New techniques for breast irradiation after breast conserving
surgery are emerging, such as partial breast irradiation using a va-
riety of methods. These techniques generally seek to reduce the
amount of normal tissue radiated in order to reduce the incidence
of acute and late side effects. However, there is also one ongoing
trial (MA20) examining the role of nodal irradiation after con-
servative surgery, which will, if favourable, increase the volume
of tissue radiated (Olivotto 2003). Changes to the fractionation
used for radiotherapy after conservative surgery should also lead to
less time being needed for radiotherapy (Whelan 2002). If these
techniques are effective, this may allow radiotherapy to be deliv-
ered quickly and easily, before prolonged courses of chemother-
apy. There is currently no reliable information regarding the best
sequencing of chemotherapy with these radiotherapy techniques.
(4) Concurrent administration of modern chemotherapy and ra-
diotherapy
The concurrent use of chemotherapy and radiotherapy minimises
any delay in starting radiotherapy and the concurrent use of CMF
and radiotherapy does not appear to affect objectively measured
acute or late cosmetic outcomes or complications (Arcangeli 2006;
Faul 2003; Lamb 1999). There is some non-randomised evidence
that the concurrent use of moremodern anthracycline chemother-
apy and radiotherapy is associated with more high-grade skin tox-
icity and higher hospitalisation rates, which have been deemed by
some to be unacceptable (Fiets 2003). We identified one ongoing
study, which has completed accrual but not follow up, which will
provide information about the feasibility and effectiveness of con-
current radiotherapy and anthracyclines (Fernando 1999). Finally,
some researchers maintain that the concurrent use of radiotherapy
and paclitaxel is feasible and have reported its use without dose
reductions, pneumonitis or brachial plexopathy (Formenti 2003).
However, others have reported pneumonitis rates as high as 14%
and have concluded that caution is required (Taghian 2001).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from three well conducted randomised trials indicates
that local control and survival is similar for concurrent chemo-
therapy and radiotherapy, radiotherapy followed by chemother-
apy, and chemotherapy followed by radiotherapy for women with
early breast cancer when the radiotherapy is commenced within
seven months after surgery.
Implications for research
Randomised trials are needed to assess the relative effects of se-
quencing traditional and new radiotherapy techniques with new
chemotherapy regimens and biological therapies, including tax-
anes andHerceptin. Future trials should collect data on costs, qual-
ity of life, and patient preference; as well as on local and distant
recurrence, cause specific mortality and harms.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arcangeli 2006
Methods Accrual: January 1997 to November 2002
Single centre, Italy
Randomisation balanced to strata: method not specified
Stratified according to tumour diameter, age and lymph node status
Baseline: no differences
Power calculation
Participants 206 women with breast cancer (pT1-2N0-1M0), who had quadrantectomy and axillary dissection, neg-
ative margins, no previous radiotherapy
Age 18 to 76 years
Interventions Experimental: concurrent (CMF synchronous with radiotherapy)
Control: sequential (CMF, then radiotherapy at seven months)
CMF: includes cyclophosphamide 600mg/m2,mg/m2, intravenously days 1,8, every 28 days, six cycles
Radiotherapy: 50Gy/20 fractions + boost 10 Gy/6 fractions
Outcomes Primary: breast recurrence-free interval
Other: overall survival, locoregional recurrence, distant metastases, toxicity
Notes Median follow up: 65 months
All randomised patients used in time-to-event analyses
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Bellon 2005
Methods Accrual: June 1984 to October 1992
Multicentre, USA
Randomisation method not specified
Stratified by: number of nodes involved, menopausal status
Baseline imbalances: radiotherapy first group had more patients with tumour size 1 to 2 cm and intra
ductal component. Had fewer patients with boost dose of 16 Gy or higher
Power calculation
Participants 244 women with stage I or II breast cancer who had undergone conservative therapy (excision of all gross
disease and level I/II axillary dissection)
Age 20 to 68 years
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Bellon 2005 (Continued)
Interventions Experimental: radiotherapy then chemotherapy
Control: chemotherapy then radiotherapy
Chemotherapy : CAMFP 4 cycles, given every 21 days (Cyclophosphamide 500mg/m2, doxorubicin
45mg/m2, methotrexate 40mg/m2, 5-fluorouracil 500mg/m2, prednisone 40mg/m2, leucovorin 10mg/
m2, orally, four times per day, days 2 to 4, 16 to 18)
Radiotherapy: 45Gy/25 fractions +16 to 18Gy boost
Outcomes Overall survival (10 years), event-free survival, local recurrence, distant/regional recurrence
Notes Median follow up: 135 months (range: 17 to 196)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Calais 2004
Methods Accrual: March 1996 to May 2000
Multicentre, France
Patients were stratified according to axillary status
Randomisation method not specified
Baseline imbalances: the two groups were balanced regarding age, stage, performance status, histology,
hormonal receptors, tumour margins, in situ components and axillary status
Participants 647 women who had breast conserving surgery for breast cancer
Median age: experimental group 58.6 years, control group 49.5 years
Interventions Experimental: chemotherapy and radiotherapy concurrently
Control: chemotherapy followed by radiotherapy sequentially
Chemotherapy: 5-fluorouracil 500mg/m2, mitoxantrone 12mg/m2, cyclophosphamide 500mg/m2: six
cycles given at 21 days
Radiotherapy: 50Gy with or without 10 to 20Gy boost to tumour bed. Boost given if there were factors
for local recurrence (not specified): given during cycles 1 to 3 of chemotherapy (experimental) or after
chemotherapy (control)
Outcomes Local and regional recurrences, distant metastases, secondary cancers, overall survival, acute toxicity,
protocol adherence, antitumour effects
Notes Median follow up: 36 months
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Assersohn 1999 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria
Bellantone 1998 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria: treatments were given before surgery rather than after surgery, as required by our inclusion criteria
Bellon 2002 Not a randomised trial
Bellon 2004 Not a randomised trial
Blomqvist 1992 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria
Buzdar 1993 Not a randomised trial
Cakir 2003 Not a randomised trial
Denham 1995 Not a randomised trial
Donato 2004 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy in post-surgery patients with
early stage breast cancer, as required by our inclusion criteria
Dubey 1999 Not a randomised trial
Faul 1998 Not a randomised trial
Faul 2003 Not a randomised trial
Fiets 2003 Not a randomised trial
Garcia 1996 Not a randomised trial
Hartsell 1995 Not a randomised trial
Hasbini 2000 Not a randomised trial
Isaac 2002 Not a randomised trial
Lamb 1999 Not a randomised trial
Leonard 1995 Not a randomised trial
Recht 1991 Not a randomised trial
Rouesse 2002 Randomised trial, but confounded by different chemotherapy regimens in the two study groups
Rubens 1980 Not a randomised trial
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(Continued)
Sauer 1996 Not a randomised trial
Stemmer 2003 Not a randomised trial
Wallgren 1996 Sequences of adjuvant chemotherapy and adjuvant radiotherapy were not consistent with our inclusion criteria
Warner 1998 Did not compare sequences of adjuvant radiotherapy and adjuvant chemotherapy, as required by our inclusion
criteria
Zambetti 1999 Not a randomised trial
Characteristics of ongoing studies [ordered by study ID]
Fernando 1999
Trial name or title SECRAB
Methods
Participants Women with histological diagnosis of invasive breast cancer who had undergone wide local excision or
mastectomy
Interventions Sequential chemotherapy/radiotherapy and ’sandwich’ chemotherapy/radiotherapy/chemotherapy
Outcomes Primary endpoint: local recurrence at 5 years
Secondary endpoints: distant metastases, relapse rates, overall survival at 5, 10 and 15 years. A sample of 300
will be studied for toxicity, cosmesis and quality of life
Starting date 1998
Contact information Dr Sarah Bowden
Inst for Cancer Studies
University of Birmingham
Vincent Drive
Edgbaston
Birmingham
B15 2TT
UK
Tel: +44-121-4144371
Fax: +44-121-4143700
s.j.bowden@bham.ac.uk
Notes ISRCTN 84214355
Multi-centred randomised controlled trial
Setting: UK
Accrual completed
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D A T A A N D A N A L Y S E S
Comparison 1. Concurrent versus sequential (chemotherapy first)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Local recurrence 2 853 Odds Ratio (M-H, Fixed, 95% CI) 1.30 [0.45, 3.77]
2 Distant metastases 2 853 Odds Ratio (M-H, Fixed, 95% CI) 1.43 [0.86, 2.37]
3 Toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Skin toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 Oesophageal toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.3 Nausea and vomiting 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.4 Alopecia 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.5 Infection 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.6 Fever 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.7 Cardiac toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.8 Neutrophil toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.9 Platelet toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.10 Haematological toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 2. Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Skin toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Subcutaneous toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.3 Pneumonitis 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.4 Neutropaenic sepsis 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.5 Cardiac toxicity 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.6 Lymphoedema 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.7 Brachial plexopathy 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 1.1. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 1 Local
recurrence.
Review: Sequencing of chemotherapy and radiation therapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 1 Local recurrence
Study or subgroup Concurrent Sequential Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arcangeli 2006 2/106 2/100 33.7 % 0.94 [ 0.13, 6.82 ]
Calais 2004 6/327 4/320 66.3 % 1.48 [ 0.41, 5.28 ]
Total (95% CI) 433 420 100.0 % 1.30 [ 0.45, 3.77 ]
Total events: 8 (Concurrent), 6 (Sequential)
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
0.001 0.01 0.1 1 10 100 1000
Favours concurrent Favours sequential
Analysis 1.2. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 2 Distant
metastases.
Review: Sequencing of chemotherapy and radiation therapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 2 Distant metastases
Study or subgroup Concurrent Sequential Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arcangeli 2006 8/106 4/100 14.8 % 1.96 [ 0.57, 6.72 ]
Calais 2004 32/327 24/320 85.2 % 1.34 [ 0.77, 2.33 ]
Total (95% CI) 433 420 100.0 % 1.43 [ 0.86, 2.37 ]
Total events: 40 (Concurrent), 28 (Sequential)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
0.001 0.01 0.1 1 10 100 1000
Favours concurrent Favours sequential
18Sequencing of chemotherapy and radiation therapy for early breast cancer (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Concurrent versus sequential (chemotherapy first), Outcome 3 Toxicity.
Review: Sequencing of chemotherapy and radiation therapy for early breast cancer
Comparison: 1 Concurrent versus sequential (chemotherapy first)
Outcome: 3 Toxicity
Study or subgroup Concurrent Sequential Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Skin toxicity
Calais 2004 268/327 242/320 1.46 [ 1.00, 2.14 ]
2 Oesophageal toxicity
Calais 2004 111/327 84/320 1.44 [ 1.03, 2.02 ]
3 Nausea and vomiting
Calais 2004 218/327 237/320 0.70 [ 0.50, 0.98 ]
4 Alopecia
Calais 2004 95/327 105/320 0.84 [ 0.60, 1.17 ]
5 Infection
Calais 2004 53/327 52/320 1.00 [ 0.66, 1.51 ]
6 Fever
Calais 2004 44/327 35/320 1.27 [ 0.79, 2.03 ]
7 Cardiac toxicity
Calais 2004 7/327 4/320 1.73 [ 0.50, 5.96 ]
8 Neutrophil toxicity
Calais 2004 235/327 237/320 0.89 [ 0.63, 1.27 ]
9 Platelet toxicity
Calais 2004 11/327 12/320 0.89 [ 0.39, 2.06 ]
10 Haematological toxicity
Calais 2004 101/327 76/320 1.43 [ 1.01, 2.03 ]
0.001 0.01 0.1 1 10 100 1000
Favours concurrent Favours sequential
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Analysis 2.1. Comparison 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy,
Outcome 1 Toxicity.
Review: Sequencing of chemotherapy and radiation therapy for early breast cancer
Comparison: 2 Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome: 1 Toxicity
Study or subgroup Radiotherapy first Chemotherapy first Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Skin toxicity
Bellon 2005 17/122 12/122 1.48 [ 0.68, 3.26 ]
2 Subcutaneous toxicity
Bellon 2005 6/122 3/122 2.05 [ 0.50, 8.40 ]
3 Pneumonitis
Bellon 2005 5/122 0/122 11.47 [ 0.63, 209.70 ]
4 Neutropaenic sepsis
Bellon 2005 21/122 8/122 2.96 [ 1.26, 6.98 ]
5 Cardiac toxicity
Bellon 2005 0/122 0/122 0.0 [ 0.0, 0.0 ]
6 Lymphoedema
Bellon 2005 0/122 4/122 0.11 [ 0.01, 2.02 ]
7 Brachial plexopathy
Bellon 2005 1/122 0/122 3.02 [ 0.12, 74.98 ]
0.1 0.2 0.5 1 2 5 10
Favours RT first Favours CT first
A D D I T I O N A L T A B L E S
Table 1. Radiotherapy then chemotherapy versus chemotherapy then radiotherapy
Outcome Number of trials Sample Size OR/HR (95% CI) OR P-value Heterogen. P-value
Overall survival 1 224 0.85 (0.51to 1.4) 0.52 N/A
Distant metastases 1 244 0.82 (0.49 to 1.36) 0.44 N/A
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